RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Prostate Cancer Channel

subscribe to Prostate Cancer newsletter
Latest Research : Cancer : Prostate Cancer

   EMAIL   |   PRINT
NICE Supports High Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer

Apr 3, 2005 - 9:56:00 AM
It is particularly suited to patients who are not candidates for surgery or those for whom radiotherapy treatment has failed. In contrast to surgery, it requires only a short period of hospitalization and has a low complication rate. Unlike radiation, HIFU treatment can also be safely repeated if necessary.

 
[RxPG] EDAP TMS S.A. (Nasdaq: EDAP - News), today welcomed the publication of the U.K. National Institute for Clinical Excellence (NICE) recent guidelines supporting the use of High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer.

More than 27,000 men in the U.K. are being diagnosed with prostate cancer every year, and 10,000 die from the disease.

HIFU with AblathermĀ® significantly broadens the range of treatment options for patients with localized prostate cancer, offering an alternative therapy for the patients.

It is particularly suited to patients who are not candidates for surgery or those for whom radiotherapy treatment has failed. In contrast to surgery, it requires only a short period of hospitalization and has a low complication rate. Unlike radiation, HIFU treatment can also be safely repeated if necessary.

HIFU with Ablatherm has established strong credentials with 7,000 treatments performed to date worldwide using the Ablatherm. In the U.K., Stepping Hill Hospital, Stockport, was the first institution in the country to use HIFU with Ablatherm for the treatment of prostate cancer. It has been treating patients for more than a year, as part of a clinical pilot trial, with very encouraging outcome.

Dr. Stephen Brown, consultant urologist at Stepping Hill Hospital, Stockport, commented: "In Europe there is increasing experience with many new centers coming on line and large numbers of patients being treated. When we started a year ago we wanted to embark on a U.K. study to establish whether it is as good as the Europeans are claiming. Results so far are very encouraging. Patients seem very happy with the treatment, but it's still very early days."

Hugues de Bantel, Chief Executive Officer of EDAP TMS, added: "We very much welcome these supportive guidelines from NICE. They provide a positive springboard for our continuing efforts to educate both clinicians and patients in the U.K. about the benefits of HIFU with Ablatherm treatment options. Ablatherm is now officially recognized in the U.K."



Publication: U.K. National Institute for Clinical Excellence (NICE) recent guidelines on Prostate Cancer treatment
On the web: EDAP TMS S.A. 

Advertise in this space for $10 per month. Contact us today.


Related Prostate Cancer News
Abiraterone has been approved for men with metastatic prostate cancer that is no longer responsive to therapy with hormones and docetaxel
Virus associated with prostate cancer tumors and chronic fatigue syndrome unlikely to be the cause
Acupuncture helps with side effects of prostate cancer treatment
Surgery superior to drug therapy for symptoms of benign prostatic hypertrophy
Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer
Inhibition of TNF-receptor associated protein-1possible treatment for prostatic cancer
Oncologists present test to predict survival in castration-resistant prostate cancer patients
PSA levels appear to be predictive of three year prostate cancer risk in African-American men
Survey on PSA screening in young men
New, noninvasive prostate cancer test beats PSA in detecting prostate cancer

Subscribe to Prostate Cancer Newsletter

Enter your email address:


 Additional information about the news article
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact the Investor Relations Dept by phone at +33 (0)4 78 26 40 46 or see the Company's Web site.

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.
CONTACT: EDAP TMS S.A.
Hugues de Bantel - Philippe Chauveau
Blandine Confort
+33 4 78 26 40 46
Halliburton Investor Relations
Matt Kreps - Geralyn DeBusk
972 458 8000
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

Ā© All rights reserved by RxPG Medical Solutions Private Limited (India)